GlaxoSmithKline PLC (NYSE:GSK) Given Average Recommendation of “Hold” by Brokerages

GlaxoSmithKline PLC (NYSE:GSK) has received a consensus recommendation of “Hold” from the twenty-two analysts that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $45.67.

GSK has been the subject of a number of recent research reports. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. ValuEngine cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub cut shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded down 0.28% during mid-day trading on Friday, reaching $38.79. 2,329,225 shares of the company’s stock were exchanged. The stock has a market cap of $94.80 billion, a price-to-earnings ratio of 37.51 and a beta of 1.03. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59. The stock’s 50-day moving average is $41.84 and its 200-day moving average is $41.84.

GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities analysts expect that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 annualized dividend and a dividend yield of 5.06%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Carroll Financial Associates Inc. increased its position in GlaxoSmithKline PLC by 0.4% in the second quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock valued at $374,000 after buying an additional 35 shares in the last quarter. King Luther Capital Management Corp increased its position in GlaxoSmithKline PLC by 1.0% in the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after buying an additional 55 shares in the last quarter. First National Bank of Omaha increased its position in GlaxoSmithKline PLC by 0.3% in the second quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock valued at $827,000 after buying an additional 57 shares in the last quarter. Pekin Singer Strauss Asset Management IL increased its position in GlaxoSmithKline PLC by 1.1% in the first quarter. Pekin Singer Strauss Asset Management IL now owns 5,516 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 60 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its position in GlaxoSmithKline PLC by 1.9% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after buying an additional 64 shares in the last quarter. 8.96% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/11/brokerages-set-glaxosmithkline-plc-nysegsk-pt-at-45-67-updated-updated-updated.html.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

What are top analysts saying about GlaxoSmithKline PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit